Rates of Renal, Thyroid Carcinomas Increasing in Children, Adolescents

Article

Results of a new study show that cancer rates among children and adolescents are stable, but rates of certain cancers such as renal carcinomas are increasing.

Results of a new study show that overall cancer rates among children and adolescents are stable, but that the incidence of certain cancers, including renal and thyroid carcinomas, are increasing.

“These findings highlight an opportunity to improve our knowledge of the driving factors of these cancer incidence rate trends, and this understanding may help develop new preventive measures,” wrote David A. Siegel, MD, MPH, of Emory University School of Medicine, and colleagues in Pediatrics.

Siegel and colleagues analyzed data taken from the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) registries to identified cancer diagnosed in patients aged 0 to 19 years between 2001 and 2009. According to the study, these registries represent 94.2% of the US population.

Using these registries, they identified 120,137 cases of cancer, with an age-adjusted incidence rate of 171.01 per million. Data showed that the incidence of cancer was higher in boys compared with girls, in adolescents compared with children, and in white children compared with black children. The most commonly occurring cancers were leukemia, followed by central nervous system neoplasms, and lymphomas.

The researchers found no significant change in the cancer incidence from 2001 to 2009 (annual percent change [APC], 0.3%; 95% CI, -0.1 to 0.7). However, they did find that the incidence of thyroid carcinoma (APC, 4.9%; 95% CI, 3.2 to 6.6) and renal carcinoma (APC, 5.4%; 95% CI, 2.8 to 8.1) had increased significantly.

“Rates of renal carcinomas, thyroid carcinomas, and other unspecified malignant neoplasms increased significantly for boys, and the trend for thyroid carcinoma increased significantly for girls,” the researchers wrote. “Increased rate of obesity among adolescents might explain increases in renal carcinomas observed overall and among those aged 15 to 19 years.”

In addition to the results about thyroid and renal carcinoma, the study also found an increasing trend in the overall cancer incidence among black children and adolescents (APC, 1.3%; 95% CI, 0.2 to 2.5). A significant decrease in melanoma was seen overall, as well as in boys, white patients, non-Hispanic patients, adolescents aged 15 to 19 years, and in the Northwest and West regions.

“It is possible that pediatric melanoma is decreasing after an increase seen at the end of the last century,” the researchers wrote. “However, melanoma is often an outpatient disease that adds registry data late into SEER and NPCR.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content